Overall, the use of 5-aminosalicylic acid (5-ASA) in combination with ustekinumab (UST) did not provide a significant benefit in patients with inflammatory bowel disease (IBD). Evidence Rating Level: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback